GlobeNewswire by notified

Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)

Share
  • Extending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025

  • Both parties strengthening focus on antibiotic stewardship and planning to engage in AMR surveillance and efforts to repurpose existing antibiotics.

  • Collaboration focuses on next-generation sequencing (NGS) and AI-assisted bioinformatics solutions for surveillance and drug repurposing efforts

Basel, April 6, 2022 — Sandoz today announces the extension and expansion until January 31, 2025 of its strategic collaboration agreement with Ares Genetics (Ares), aimed at driving cutting-edge digital solutions in the global fight against antimicrobial resistance (AMR).

The extension of the existing master services agreement with Ares, a subisidiary of OpGen Inc, reflects both companies’ recognition of the critical importance of surveillance data to inform better prescribing and use of antibiotics – a central component of the global AMR response strategy.

Sandoz CEO Richard Saynor said: “Antibiotics are the cornerstone of modern medicine. AMR, which is now estimated to directly account for nearly 1.3 million deaths worldwide every year, is an unprecedented threat to global public health. As the world’s leading provider of generic antibiotics, our goal at Sandoz is to play a key role in overcoming this growing threat.

“This collaboration is a key step towards that goal, allowing us to take the fight directly to AMR by using cutting-edge big data and AI approaches combined with traditional data sets. By combining our respective skillsets, we believe we can not only use diagnostic and surveillance data to help healthcare professionals make better diagnoses, but also expand our options to treat AMR in the future, by targeted repurposing of key antibiotics. Our ultimate goal is both simple and radical: to ensure we get the right medicine to the right patient at the right time.”

During the initial stage of the collaboration, Ares developed a digital anti-infectives platform, combining established microbiology laboratory practices with advanced bioinformatics and AI methods to support the identification of effective antimicrobial compounds or compound combinations to address critical pathogens, which Sandoz can in turn leverage to drive portfolio and commercial decisions.

In the upcoming next phase, both collaboration parties intend to focus further on antibiotic stewardship by enabling genomic surveillance for resistant pathogens, using Ares’ next-generation sequencing (NGS) and bioinformatics technologies. Financial details are not being disclosed at this stage.

Disclaimer
This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that, if approved, such generic or biosimilar products will be approved for all indications included in the reference product’s label. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.

About Sandoz
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering major therapeutic areas, accounted for 2021 sales of USD 9.6 billion.

Sandoz on social media:
LinkedIn: https://www.linkedin.com/company/sandoz
Twitter: https://twitter.com/sandoz_global
Facebook: https://www.facebook.com/sandozglobal/
Instagram: https://www.instagram.com/sandozglobal
CEO Richard Saynor on LinkedIn: https://www.linkedin.com/in/richard-saynor/

Novartis and Sandoz Global Communications

E-mail: media.relations@novartis.com



Richard Jarvis
Novartis Global Communications
+41 79 584 23 26 (mobile)
richard.jarvis@novartis.com


Chris Lewis
Sandoz Global Communications
+49 174 244 9501 (mobile)
chris.lewis@sandoz.com

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

CentralNorth America
Samir Shah+41 61 324 7944Sloan Simpson+1 862 778 5052
Nicole Zinsli-Somm        
Isabella Zinck
+41 61 324 3809
+41 61 324 7188
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Interim results for the period ended March 31, 202226.5.2022 13:30:47 CEST | Press release

Golar LNG Limited ("Golar" or "the Company") reports Q1 2022 ("Q1") Net income of $345.2 million.Adjusted EBITDA1 of $93.4 million for the quarter inclusive of FLNG Hilli, Golar Arctic and Golar Tundra but excluding the 8 TFDE vessels and management companies sold to Cool Company Ltd. ("CoolCo"). Sold 6.2 million New Fortress Energy Inc. ("NFE") shares in Q2 2022 ("Q2") realizing net cash proceeds of $253 million. Golar now owns 12.4 millionNFE shares following the sale.Q1 Total Golar Cash and Listed Securities1 position increased by $0.4 billion to $1.3 billion. Golar's share of Contractual Debt1 decreased by $0.5 billion to $1.7 billion in Q1 and a further $0.5 billion in Q2 after sale of remaining carriers to CoolCo in April.Agreed to sell the steam turbine carrier Golar Arctic as a converted FSRU to Italy's Snam for 269 million Euros ($288 million). Strong progress made on opportunities for FSRU Golar Tundra and on pipeline of FLNG projects. Shipping spin-off: A key focus for Q1 wa

Dante Labs highlights advancements to its drug discovery development program, demonstrating the value of genomic data to drug discovery26.5.2022 13:30:00 CEST | Press release

– Company announces rebranding to Dante Genomics to reflect its broader global efforts – NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Dante Genomics, a global leader in genomics and precision medicine, highlights significant progress made in its drug discovery development program with six drug candidates currently in the Company’s pipeline, applying Dante’s internal siRNA and mRNA technology to rare and common diseases. Since the company’s foundation, Dante has invested in a robust R&D program with the goal to create end-to-end solutions from diagnosis to therapy. Dante’s program began with a focus on rare disease, in response to a diagnosis of a patient with a rare disease for which there were no treatment therapies. Dante’s pipeline has evolved across multiple disease areas with four drug programs in full internal development and two in co-development to achieve validation and partner externally on clinical trials and commercialization. “Personalized medicine needs personalized data, a

Tilray Launches CBD Lifestyle Brand, Pollen, on Amazon UK26.5.2022 13:00:00 CEST | Press release

Innovative, Delicious CBD Designed to Make You Feel Your Kind of Good LONDON, May 26, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (NASDAQ | TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today announced the launch of POLLEN, a CBD lifestyle brand with a new approach to wellness, on Amazon UK. Designed to help uncomplicate wellness routines and elevate the CBD experience for consumers, POLLEN offers a unique product mix of tasty CBD gummies and drink drops in three signature lines; ‘Powerbank’ to promote a natural energy boost, ‘No Pressure’ to soften the pressure of everyday stresses and restore your body’s natural bounce, and ‘Soothe You’ for mind and body balance. Each POLLEN product is formulated with CBD and a range of flavorful and vegan-friendly ingredients that simply taste and feel good. Powerbank - Developed to give you that ‘full tan

Sinch resolves on an in-kind issue of shares to the sellers of Pathwire26.5.2022 10:00:00 CEST | Press release

Stockholm, Sweden – 26 May 2022 – Sinch AB (publ) (the “Company” or “Sinch”), a global leader in cloud communications for mobile customer engagement, today announces that the board of directors, in accordance with what was communicated on 7 December 2021, has resolved on an in-kind share issue of 25.5 million shares to the sellers of Pathwire. On 30 September 2021, Sinch disclosed that it had entered into an agreement to acquire Pathwire and the acquisition was completed on 7 December 2021. In addition to the cash consideration, Sinch shall issue an aggregate of 51 million shares in the Company as consideration to the sellers, of which the first 25.5 million shares were issued in February 2022. The board of directors has today resolved to issue the remaining 25.5 million of these shares. The payment of the shares consists of a receivable, under the agreement for the acquisition of Pathwire, against two of the company’s subsidiaries. The contributed receivable amounts to the remaining U

Sinch beslutar om apportemission av aktier till säljarna av Pathwire26.5.2022 10:00:00 CEST | Pressemelding

Stockholm, Sverige – 26 maj 2022 – Sinch AB (publ) (”Bolaget” eller ”Sinch”), en ledande global leverantör av molntjänster för kundinteraktion via mobilen, meddelar idag att styrelsen, i enlighet med vad som har kommunicerats i pressmeddelande den 7 december 2021, har beslutat om apportemission av 25,5 miljoner aktier till säljarna av Pathwire. Sinch offentliggjorde den 30 september 2021 att avtal om att förvärva Pathwire hade ingåtts och förvärvet slutfördes den 7 december 2021. I tillägg till den kontanta köpeskillingen ska Sinch emittera sammanlagt 51 miljoner nya aktier i Sinch som del av vederlaget till säljarna, varav de första 25,5 miljoner aktierna emitterades i februari 2022. Styrelsen har idag beslutat att emittera de resterande 25,5 miljoner aktierna. Betalningen har skett genom apport av en fordran enligt avtalet avseende förvärvet av Pathwire, på två av Bolagets dotterbolag, om de återstående 500 miljoner USD (den initiala delen av fordran om 500 miljoner USD tillfördes i